List of Excipients in Branded Drug MEMANTINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	MEMANTINE HYDROCHLORIDE	memantine hydrochloride	0591-3870	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	MEMANTINE HYDROCHLORIDE	memantine hydrochloride	0591-3870	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	MEMANTINE HYDROCHLORIDE	memantine hydrochloride	0591-3870	FD&C BLUE NO. 2

Generic Drugs Containing MEMANTINE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY LLC dba Vangard Labs	memantine	0615-8100	FD&C BLUE NO. 2
NCS HealthCare of KY LLC dba Vangard Labs	memantine	0615-8100	FD&C YELLOW NO. 6
NCS HealthCare of KY LLC dba Vangard Labs	memantine	0615-8100	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in MEMANTINE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CITRIC ACID MONOHYDRATE
1	CROSCARMELLOSE SODIUM

Memantine Excipient Strategy and Commercial Opportunities

Last updated: October 6, 2026

Memantine is a mature, genericized Alzheimer’s disease drug with limited compound-level exclusivity and meaningful formulation opportunities. The strongest commercial opportunities are in swallow-friendly delivery, taste-masked oral liquids, orally disintegrating tablets, sprinkle capsules, and differentiated excipient systems that improve stability, dosing accuracy, or patient adherence.

Memantine hydrochloride is marketed primarily as immediate-release tablets, oral solution, and extended-release capsules. The active ingredient has high oral bioavailability, so commercial value is more likely to come from dosage-form convenience and tolerability than from basic absorption enhancement.[1,2]

What is the current FDA status of memantine?

Memantine hydrochloride is FDA-approved for the treatment of moderate to severe dementia of the Alzheimer’s type. Immediate-release memantine was approved in 2003, and extended-release memantine capsules were approved in 2010.[1,3]

Product type	Representative product	FDA dosage form	Typical strength range	Primary use
Immediate-release tablet	Namenda and generics	Film-coated tablet	5 mg, 10 mg	Twice-daily titration and maintenance
Oral solution	Namenda oral solution and generics	Solution	2 mg/mL	Patients unable to swallow tablets
Extended-release capsule	Namenda XR and generics	Extended-release capsule	7 mg, 14 mg, 21 mg, 28 mg	Once-daily treatment
Extended-release capsule sprinkle	Generic and branded-style products	Capsule that may be opened	Dose-specific	Patients with swallowing difficulty

The approved adult regimen for immediate-release memantine generally starts at 5 mg once daily and is titrated to 10 mg twice daily. Extended-release products are titrated to a maximum of 28 mg once daily in patients with appropriate renal function.[1,3]

Memantine is not a biologic and has no biosimilar pathway. Competition occurs through abbreviated new drug applications, pharmaceutical-equivalence requirements, formulation development, and state substitution rules.

What patents protect memantine products?

The original memantine compound and early pharmaceutical patents are expired or no longer commercially meaningful in the United States. Current commercial protection is primarily associated with formulation execution, regulatory exclusivity, trademarks, manufacturing know-how, and product-specific labeling rather than the active pharmaceutical ingredient.

Memantine’s principal U.S. product patents were filed more than two decades ago. The original immediate-release product has faced generic competition for many years. The extended-release product also has generic competition, reducing the value of the original branded formulation estate.

IP category	Commercial position
Memantine active ingredient	No meaningful U.S. composition-of-matter exclusivity
Immediate-release tablets	Generic competition established
Oral solution	Generic competition established
Extended-release capsules	Generic competition established or developing, depending on product and market
New excipient system	Potentially protectable through formulation or process claims
Taste-masked liquid	Potential formulation and trade-secret protection
ODT or multiparticulate product	Potential formulation, process, and device protection
Manufacturing process	Potential process patent and know-how protection
Packaging and dosing device	Potential device or combination-product protection

A company pursuing a differentiated memantine product should not rely on a broad “memantine plus excipient” claim. Patentability is more credible when the excipient system produces a measured technical effect, such as improved chemical stability, reduced bitterness, controlled release, lower friability, improved dose uniformity, or a defined dissolution profile.

When does memantine lose exclusivity?

Memantine has already lost practical U.S. market exclusivity for conventional immediate-release treatment. The commercial question is therefore not compound exclusivity but whether a new dosage form can obtain meaningful differentiation before competing products replicate it.

FDA approval dates provide the relevant regulatory timeline:

Milestone	Date	Commercial implication
Immediate-release memantine approval	October 2003	Original approval for Namenda
Extended-release memantine approval	February 2010	Once-daily formulation introduced
Generic immediate-release competition	Established after original exclusivity period	Price competition and substitution
Generic extended-release competition	Product- and approval-specific	Opportunity depends on formulation and supply
New formulation opportunity	Current	Requires clinical, CMC, or adherence advantage

FDA marketing exclusivity for an older small-molecule product does not prevent the development of an independently supported memantine formulation today. A new product may qualify for limited regulatory exclusivity if it meets the applicable statutory requirements, but a novel excipient combination alone does not guarantee exclusivity.

What excipients are used in memantine tablets?

Commercial immediate-release memantine tablets use conventional solid-dose excipients. Representative products contain lactose monohydrate, microcrystalline cellulose, talc, colloidal silicon dioxide, and magnesium stearate, although compositions differ by manufacturer.[4,5]

Excipient class	Representative excipients	Function in memantine tablets
Diluent	Lactose monohydrate, microcrystalline cellulose	Tablet mass and compressibility
Binder	Pregelatinized starch, povidone, microcrystalline cellulose	Granule and tablet strength
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Tablet breakup after ingestion
Glidant	Colloidal silicon dioxide	Powder flow
Lubricant	Magnesium stearate, stearic acid	Ejection and reduced tooling friction
Anti-adherent	Talc	Reduced sticking and improved processing
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Identification, swallowability, protection
Colorant	Iron oxides, titanium dioxide	Product differentiation and dose identification

Memantine hydrochloride is a relatively low-dose active ingredient. This creates substantial latitude for tablet design. The main development constraints are blend uniformity, segregation control, mechanical strength, dissolution, and compatibility with the selected filler and disintegrant.

How should excipients be selected for immediate-release memantine?

For a conventional generic tablet, the lowest-risk formulation uses well-established compendial excipients and a manufacturing process with a demonstrated dissolution match to the reference product. Direct compression can reduce process complexity, but roller compaction or wet granulation may improve content uniformity and tablet robustness when powder flow is inadequate.

A practical excipient screen should evaluate:

1. Blend uniformity at the target drug load.
2. Tablet weight and content uniformity.
3. Disintegration across relevant storage conditions.
4. Dissolution at multiple pH values.
5. Tablet friability and hardness.
6. Lubricant sensitivity.
7. Stability under high humidity.
8. Compatibility with packaging materials.

The formulation should avoid unnecessary excipient complexity. In a mature generic market, every additional excipient creates a potential source of variability, labeling burden, supply-chain exposure, or patient intolerance.

What excipients are used in memantine oral solution?

Memantine oral solutions typically use a buffered, sweetened aqueous system. Representative labeling identifies sorbitol and preservative systems such as potassium sorbate, together with citrate buffers, citric acid, and purified water.[6]

Formulation need	Potential excipient strategy
Sweetness	Sorbitol, sucralose, saccharin sodium, or other approved sweeteners
Bitterness control	Flavor systems, ion-exchange resins, cyclodextrins, or polymeric taste maskers
pH control	Citric acid, sodium citrate, phosphate buffers
Preservation	Potassium sorbate, sodium benzoate, or other justified preservative systems
Viscosity	Hydroxypropyl cellulose, xanthan gum, or other oral-grade polymers
Chelation and metal control	Disodium edetate where justified
Oxidative protection	Antioxidant system where supported by degradation data
Dosing accuracy	Low-foaming vehicle and calibrated oral syringe
Container compatibility	Amber glass or compatible high-barrier polymer packaging

The principal technical risk is not solubility alone. Memantine oral solution development must address bitterness, preservative effectiveness, pH stability, microbial control, container closure compatibility, dosing-device accuracy, and patient acceptance.

What commercial opportunities exist for a memantine liquid?

A liquid product can target patients with dysphagia, advanced dementia, feeding-tube use, or caregiver-administered medication. The most attractive positioning is a ready-to-use, alcohol-free, sugar-free, low-volume product with a calibrated oral syringe and a taste profile that supports repeated dosing.

Potential commercial differentiators include:

• A lower-viscosity liquid that reduces dosing residue.
• A sugar-free formulation suitable for patients requiring sugar restriction.
• A preservative-reduced or preservative-free presentation supported by packaging and stability data.
• A unit-dose cup or oral syringe system for caregiver administration.
• A taste-masked formulation that reduces refusal and spitting.
• A concentrated presentation that lowers administration volume.
• A tube-compatible formulation supported by delivery and recovery studies.

Taste masking is likely to provide more practical value than a nominal improvement in dissolution. Memantine products are administered chronically, and caregivers often control administration. Palatability and dosing simplicity can influence refill persistence even when the active ingredient is therapeutically interchangeable.

What formulations are protected by memantine patents?

The most defensible new IP targets are formulation attributes supported by reproducible data. These may include:

• Controlled-release multiparticulates.
• Once-daily or twice-daily release profiles.
• Taste-masked oral solutions.
• Orally disintegrating tablets.
• Sprinkle capsules containing coated pellets.
• Low-dose pediatric-style or geriatric-friendly presentations.
• Stable formulations with reduced degradation products.
• Tube-administration systems.
• Drug-device combinations with metered dosing.
• Process controls that improve blend uniformity or reduce manufacturing defects.

A patent application should define the formulation through measurable parameters rather than a broad list of excipients. Examples include a dissolution range at specified time points, a particle-size distribution, a coating weight gain, a pH range, a viscosity window, or a stability threshold.

The strongest formulation claims usually combine:

1. Memantine or memantine hydrochloride.
2. A defined functional excipient class.
3. A specific dosage form.
4. A measurable performance characteristic.
5. A manufacturing or packaging condition that contributes to the result.

How does memantine extended release use excipients?

Extended-release memantine depends on multiparticulate or matrix-based release control. Representative extended-release capsules use coated drug-containing particles or pellets placed inside a capsule shell. The release system may contain polymers such as ethylcellulose, hypromellose, or other rate-controlling materials, with plasticizers and anti-tacking agents used during coating.[7]

Release-control component	Technical purpose
Drug-layer binder	Adheres memantine to starter cores or creates robust granules
Polymer coating	Controls water penetration and drug diffusion
Plasticizer	Reduces coating brittleness
Anti-tacking agent	Prevents pellet agglomeration
Pore former	Adjusts release rate
Capsule shell	Protects and delivers the multiparticulate dose
Seal coat	Separates drug layer from functional coating

Multiparticulates have a commercial advantage in patients who cannot swallow conventional tablets. A capsule that can be opened and sprinkled over soft food may offer a meaningful adherence advantage, provided the labeling supports the method and the food does not disrupt release performance.

The principal development risks are dose dumping, pellet fracture, coating variability, food effects, moisture sensitivity, and accidental chewing. A sprinkle product requires packaging and labeling that clearly prevent crushing or chewing of the extended-release particles.

What is the Orange Book status of memantine?

Memantine immediate-release and oral-solution products are listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The relevant listings support generic substitution where an approved product has an “AB” rating and state law permits substitution.[8]

Orange Book analysis should distinguish:

• Reference listed drug status.
• Therapeutic-equivalence rating.
• Active listed patents.
• Pediatric exclusivity.
• Product-specific exclusivity.
• Whether a formulation has an independent reference product.

For an entrant, the Orange Book is more important as a regulatory and substitution tool than as a source of continuing compound protection. A new memantine product must assess whether it is an ANDA product, a 505(b)(2) application, or another regulatory pathway. A substantially altered dosage form, delivery system, or clinical use may require a 505(b)(2) strategy rather than a conventional ANDA.

Which companies are challenging memantine products?

Generic competition has come from multiple established generic manufacturers, including companies such as Teva, Sandoz, Sun Pharma, Dr. Reddy’s Laboratories, and other FDA-approved suppliers, depending on dosage form and market year. The supplier group varies by strength, formulation, and current product availability.

The commercial challenge is fragmented competition rather than a single challenger. Immediate-release tablets are generally the most exposed to price erosion. Oral solution and extended-release products can retain more value when they have fewer suppliers, more demanding manufacturing requirements, or device and packaging differentiation.

A supplier should monitor:

• FDA approval of new ANDAs.
• Drug shortages and supply interruptions.
• Authorized generic arrangements.
• Wholesale acquisition price changes.
• Medicaid and Medicare reimbursement.
• Pharmacy benefit manager substitution.
• Product discontinuation notices.
• 180-day generic exclusivity events, where applicable.

Are there Paragraph IV challenges for memantine?

Paragraph IV risk is most relevant when a proposed generic applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For mature memantine immediate-release products, the main commercial risk is established generic substitution rather than a future first Paragraph IV event.

For an extended-release or newly reformulated product, Paragraph IV exposure depends on the current Orange Book listings and the scope of any formulation patents. A formulation sponsor should expect challenges if the product reaches meaningful sales and has claims that could block an ANDA applicant.

Relevant litigation questions include:

• Whether the patent claims the active ingredient or only the dosage form.
• Whether the proposed generic uses the same release mechanism.
• Whether an ANDA applicant can design around the coating or matrix.
• Whether the patent claims a method of use rather than a formulation.
• Whether the listed patent is eligible for Orange Book submission.
• Whether a 30-month stay applies under the Hatch-Waxman framework.

No current litigation conclusion should be drawn from historical memantine cases without checking the specific product, patent, court docket, and Orange Book listing.

What manufacturing and IP barriers exist for memantine?

Immediate-release tablets have low manufacturing barriers. The greater barriers arise in liquid and extended-release products.

Immediate-release tablet barriers

• Low-dose blend uniformity.
• Segregation during transfer.
• Tablet color and imprint consistency.
• Dissolution matching.
• Lubrication control.
• Stable supply of lactose, cellulose, and coating materials.

Oral-solution barriers

• Taste masking.
• Preservative effectiveness.
• pH drift.
• Microbial control.
• Syringe dosing accuracy.
• Container compatibility.
• Extractables and leachables.
• Stability after opening.

Extended-release barriers

• Pellet coating uniformity.
• Scale-up of fluid-bed coating.
• Dose dumping control.
• Food-effect management.
• Moisture protection.
• Sprinkle performance.
• Resistance to chewing and crushing.
• Consistent dissolution over shelf life.

Manufacturing know-how can provide commercial protection even when patents are narrow. However, know-how is difficult to defend if a competitor can reproduce the product through routine reverse engineering.

What licensing opportunities exist for memantine formulations?

Memantine licensing opportunities are more likely to involve platforms than the active ingredient. Potential deal structures include:

Opportunity	Likely counterparty	Commercial rationale
Taste-masked oral solution	Generic manufacturer or specialty-pharma company	Differentiates a mature active
ODT technology	Drug-delivery platform company	Addresses dysphagia and caregiver administration
Sprinkle multiparticulates	Generic or branded-generic company	Supports swallowing-impaired patients
Oral syringe and packaging system	Device company	Improves dosing accuracy
Stable preservative-reduced liquid	Formulation company	Supports premium positioning
Tube-compatible formulation	Long-term-care supplier	Targets institutional administration
Regional commercialization rights	Local pharmaceutical company	Extends geographic reach

Licensing value depends on clinical substitutability, manufacturing cost, regulatory pathway, patent term, and payer recognition. A formulation with no meaningful adherence or administration advantage is unlikely to command a large premium in a generic market.

How strong is the patent estate for a new memantine formulation?

The baseline patent estate for conventional memantine is weak because the active ingredient and standard dosage forms are mature. A new formulation can create a stronger estate only if it demonstrates a defined technical advantage.

Patent strategy	Relative strength	Main vulnerability
Memantine plus conventional tablet excipients	Low	Routine optimization and obviousness
New tablet coating color or excipient substitution	Low	Limited technical effect
Taste-masked oral solution	Moderate	Design-around and weak clinical differentiation
ODT with rapid disintegration and masking	Moderate	Prior art and reproducibility
Multiparticulate extended release	Moderate to strong	Alternative release technologies
Tube-compatible dosage form	Moderate	Label and performance requirements
New manufacturing process	Moderate	Reverse engineering and process proof
Device-linked dosing system	Moderate	Device substitution and combination-product scope

The strongest commercial patent position would combine formulation claims, process claims, use claims where available, and device or packaging claims. The portfolio should avoid dependence on a single narrow excipient ratio.

What generic launch risks exist for memantine?

Generic launch risk is highest for standard immediate-release tablets because multiple suppliers can manufacture the product and pharmacy substitution is straightforward. Risk is lower for differentiated liquids and multiparticulate products, but those products face more regulatory and manufacturing complexity.

High-risk scenarios

• A low-cost supplier enters a tablet strength with existing therapeutic-equivalence support.
• A major wholesaler adds a second source.
• A payer changes formulary status.
• An authorized generic undercuts a branded-generic product.
• Several suppliers compete for the same institutional contracts.

Lower-risk scenarios

• The product has a well-supported taste-masking system.
• The formulation is difficult to replicate economically.
• The product includes a validated oral syringe and caregiver-friendly packaging.
• The product has limited direct competition in oral solution or sprinkle form.
• The sponsor has a reliable supply advantage.

How does memantine compare with competing Alzheimer’s drugs?

Memantine occupies a different formulation and patent position from newer disease-modifying Alzheimer’s products.

Drug	Type	Formulation opportunity	Patent position	Key commercial issue
Memantine	NMDA receptor antagonist	Liquid, ODT, ER sprinkle	Mature and weak at compound level	Adherence and low-cost competition
Donepezil	Acetylcholinesterase inhibitor	ODT, liquid, transdermal	Mature	Broad generic availability
Rivastigmine	Acetylcholinesterase inhibitor	Patch, capsule, liquid	Patch delivery remains more differentiated	Device and transdermal manufacturing
Galantamine	Acetylcholinesterase inhibitor	ER capsule, liquid	Mature	Generic substitution
Lecanemab	Monoclonal antibody	Intravenous infusion	Active biologic and method-of-use estate	Infusion infrastructure and safety monitoring
Donanemab	Monoclonal antibody	Intravenous infusion	Active biologic estate	Patient selection and monitoring

Memantine’s opportunity is operational rather than high-priced specialty innovation. A formulation that reduces caregiver burden may have stronger market value than one that produces only a small pharmacokinetic change.

What is the revenue exposure for memantine formulation developers?

Revenue exposure depends on product type and channel.

Product	Pricing pressure	Differentiation potential	Likely buyer
Standard tablet	Very high	Low	Retail pharmacy and wholesalers
Oral solution	Moderate	Moderate	Retail, long-term care, caregivers
Extended-release capsule	Moderate to high	Moderate	Retail and specialty generic channels
ODT	Moderate	Moderate to high	Retail and caregiver markets
Sprinkle capsule	Moderate	High	Long-term care and dysphagia market
Device-linked liquid	Lower if clinically accepted	High	Institutional and specialty channels

The largest opportunity is not necessarily the largest patient population. A smaller product with reliable supply, less competition, and a clear administration benefit can produce better margins than a high-volume tablet subject to aggressive generic pricing.

Key Takeaways

• Memantine has no meaningful remaining U.S. compound-level exclusivity.
• Standard immediate-release tablets are highly commoditized.
• Oral solution, ODT, and sprinkle formulations provide the clearest excipient-driven opportunities.
• Taste masking, dosing accuracy, stability, and caregiver usability are more valuable than minor dissolution changes.
• Extended-release multiparticulates have higher manufacturing barriers and stronger potential differentiation.
• New patents should claim measurable technical effects, not generic combinations of memantine and common excipients.
• Orange Book analysis remains essential for product-specific patent and substitution review.
• Memantine has no biosimilar risk because it is a small-molecule drug.
• Licensing value is concentrated in formulation platforms, devices, packaging, and manufacturing know-how.
• A commercially credible product should target dysphagia, caregiver administration, long-term-care use, or adherence rather than compete only on tablet price.

FAQs About Memantine Excipient and Formulation Strategy

Can memantine be formulated as an orally disintegrating tablet?

Yes. An ODT can use superdisintegrants, porous carriers, flavor systems, and taste-masking technology. The critical development requirements are rapid disintegration, acceptable mouthfeel, low friability, dose uniformity, and effective bitterness control.

Is memantine compatible with sugar-free oral-liquid formulations?

Yes. Sorbitol, sucralose, or other sugar-free systems can be evaluated, subject to tolerability, microbial stability, preservative effectiveness, and product-specific FDA requirements.

Which excipient provides the best taste masking for memantine?

No single excipient is universally optimal. A successful system may combine a sweetener, flavor, buffer, viscosity modifier, ion-exchange resin, cyclodextrin, or polymeric coating. Selection depends on bitterness intensity, dose concentration, stability, and release requirements.

Can memantine extended-release capsules be opened and sprinkled on food?

Some extended-release products are labeled for opening and sprinkling, but the instruction is product-specific. Multiparticulates must remain intact and should not be crushed or chewed because that can alter release.

Is a new memantine formulation eligible for a 505(b)(2) application?

A substantially modified dosage form, delivery system, or clinical presentation may be eligible for a 505(b)(2) application if the sponsor can rely in part on FDA findings for an approved product while providing required new data. The pathway depends on the formulation and proposed labeling.

References

1. U.S. Food and Drug Administration. (2003). Namenda (memantine hydrochloride) tablets prescribing information.
2. U.S. Food and Drug Administration. (2024). Memantine hydrochloride tablets prescribing information.
3. U.S. Food and Drug Administration. (2010). Namenda XR (memantine hydrochloride) extended-release capsules prescribing information.
4. DailyMed. (2024). Memantine hydrochloride tablet, film coated: Product labeling. National Library of Medicine.
5. DailyMed. (2024). Memantine hydrochloride tablet: Inactive ingredient information. National Library of Medicine.
6. DailyMed. (2024). Memantine hydrochloride oral solution: Product labeling. National Library of Medicine.
7. DailyMed. (2024). Memantine hydrochloride extended-release capsules: Product labeling. National Library of Medicine.
8. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.